6 assets in Ovarian Serous Cystadenocarcinoma

Therapeutic assets addressing Ovarian Serous Cystadenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Paclitaxel Lipid Suspension Ovarian Serous Cystadenocarcinoma	Jina Pharmaceuticals Inc.	P3	B (60)
Adavosertib Ovarian Serous Cystadenocarcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Ibentatug Ovarian Serous Cystadenocarcinoma	ZielBio, Inc.	P1/2	CCC (52)
LY3143921 Ovarian Serous Cystadenocarcinoma	Cancer Research UK	P1	CC (43)
Sapanisertib Ovarian Serous Cystadenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)
Azenosertib Ovarian Serous Cystadenocarcinoma	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	P2	NR ()